

Index

- A**
- Absorption spectroscopy, 224
 - Acousto-optical tunable filters (AOTF), 68
 - Active pharmaceutical ingredient (API)
 - MIR spectroscopy
 - crystallization, 87–88
 - reaction monitoring, 86–87
 - NIR spectroscopy
 - crystallization, 88
 - drying, 89–90
 - reaction monitoring, 87
 - Active pharmaceutical ingredients (APIs), 157, 558, 623–624, 657
 - Active transport via p-glycoprotein (ABCB1), 800
 - Adiabatic calorimetry, 391, 405
 - Aequorea victoria*, 47
 - Aerosol particle sizing
 - aerodynamic particle size measurements, 703
 - cascade impactor/impinger, 707–710
 - ELPI, 711
 - time-of-flight based measurements, 710–711
 - dispersion techniques, 703–704
 - fine particle fraction, 712–713
 - geometric particle size measurements, 703
 - laser diffraction, 706
 - microscopy/Image analysis, 707
 - OPCs, 706–707
 - in vivo situation, 713
 - pharmacopoeial requirements, 704
 - pulmonary delivery, 702
- AFM. *See* Atomic force microscopy (AFM)
- Alpha amylase (AA), 479
- 5-Aminosalicylic acid (5-ASA), 431
- Amorphous naproxen, 188
- Ampicilline, 80
- Ampoule calorimetry, 393
- Amyloid fibrils, 660
- Amyloid hydrogels, 661
- Analytical ultracentrifugation (AUC), 470
- Andersen Cascade Impactor (ACI), 708
- Anharmonic oscillator, 64
- 1-Anilino-8-naphthalenesulfonate (1,8-ANS), 36, 52
- Anomalous small angle x-ray scattering (A-SAXS), 352–354
- Anti-malarial tablets, 161
- Anti-Stokes, 142
- API. *See* Active pharmaceutical ingredient (API)
- Aripiprazole, 184
- Artificial neural networks (ANN), 71
- Asymmetrical flow field flow fractionation (AF4)
 - accumulation wall, 467
 - aggregation phenomena, 470
 - analytical ultracentrifugation, 475
 - antibody aggregates, immunogenicity testing in vivo, 481–482
 - AUC, 470
 - β -cyclodextrin-dextran polymers, 482
 - cationic polymers, gene delivery, 483
 - cross-flow, 467
 - degradation pathways, antibody-based drug candidates, 482
 - electron microscopy, 474
 - focusing step, 470–471
 - HF5, 469
 - HPLC users, 468

- Asymmetrical flow field flow fractionation (AF4) (*cont.*)
 IgG aggregates, 481
 instrumentation, 471–472
 laminar flow conditions, 467
 nanoparticulate additives, 484
 particulate systems
 DLS, 475
 electron microscopy, 475
 gelatin nanoparticles, 476–477
 HSA nanoparticles, 476
 liposomes, liposomal formulations and lipoplexes, 477–478
 melt extrusion, 477
 non-spherical nanoparticles, 479–480
 polyplexes, 479
 Stokes-Einstein equation, 475
 VLPs
 PLGA nanoparticles, 483
 polymersomes, 484
 preparative use of, 480–481
 protein aggregates, HF5, 482
 SEC, 469
 semi-preparative mode, 470
 separation technologies, 467
 separation/fractionation principle, 468
 steric mode, 473–474
- Atmospheric pressure chemical ionization (APCI), 256
- Atomic force microscopy (AFM)
 cantilevers and tips cantil. 654–655
 operating modes opermod, 652–654
 optical/spectroscopic techniques optical, 667
 pharmaceutical research, 656–657
 pharmaceutical sciences
 bacteria and bacterial biofilms bact, 665–666
 contact mode image image, 668–669
 crystal growth and polymorphism crygrow, 658
 drug-protein and protein-protein interactions, 663
 live cells live, 663–665
 nanomedicine nanaomed, 661–662
 nanotoxicology nanotox, 662
 particles and fibres parfib, 659–660
 tablet coating and dissolution table, 657
 viruses, 666–667
 polymers, 650
 principles of operation prinoper, 650–652
 SPMs, 650
- Atovaquone, 759
- ATP-binding cassette family (ABC), 792
- Attenuated total reflectance/reflection (ATR), 63, 67
- Avrami-Erofeev model, 186
- Azithromycin, 79
- B**
- Backscattered electrons (BSE), 510
- Backscattering geometry, 148
- Bagley correction method, 729
- Band target entropy minimization (BTEM), 544
- Base peak chromatogram (BPC), 266
- Basket apparatus, 756–757
- Batch calorimetry, 393
- Beer-Lambert law, 34, 176
- Bile salts (BS), 758, 774
- Binding analyses, 735
- Bingham liquid, 724
- Biofilms, 666
- Biological fluids, 745
- Bioluminescent phenomena, 29
- Biorelevant media, 759
- Biphasic dissolution apparatus, 764
- Biphasic dissolution models, 763–765
- Blood-brain barrier (BBB), 802
 bovine co-culture, 806–807
 CNS, 801
 endothelial cells and pericytes, 802
 in vitro model, 801, 803
 in vivo permeability, 803
 porcine monoculture, 805–806
 rat triple co-culture model, 804–805
 surrogate BBB models, 807
 transendothelial transport, 802
 transwell systems, 804
- Bohr frequency condition, 31
- Bohr-Grotrian diagram, 32
- Bologna stone, 31
- Boron neutron capture therapy (BNCT), 662
- Bragg's Law, 340
- Bruker Biospin Paravision™ 4.1 software, 610
- C**
- Caco-2 cell model, 793, 797–800
 change of medium, 814–815
 freezing procedure, 815
 growth medium preparation, 811
 microscopy, 810
 passage nomenclature, 818
 seeding, 812–814
 thawing procedure, 817–818
 trypsinization, 810–812
work procedure, 815–817

- Caffeine, 79
- Calorimeters, 389, 390
- DSC (*see* Differential scanning calorimetry (DSC))
 - ice calorimeters, 391
 - IMC (*see* Isothermal microcalorimeters (IMC))
- Candida parapsilosis*, 665
- Capacitively coupled conductivity detection (CCCD), 443
- Capillary-based techniques
- adsorption, 459–460
 - affinity capillary electrophoresis
 - EKC, 446
 - mobility shift affinity CE, 444
 - pre-equilibrium capillary zone and frontal analysis, 447–448
 - binding kinetics, 459
 - biomacromolecules, 440
 - charge/size ratio, 460
 - pharmaceutical applications
 - acid dissociation constants (pK_a values), 453–455
 - diffusivity and size, 457
 - interactions, excipients and delivery systems, 457–458
 - partitioning and lipophilicity, 455–456
 - physicochemical properties, 453
 - plasma protein binding, 456
 - pharmaceutical sciences
 - analysis, 442
 - bioanalysis, 440
 - physicochemical characterization, 454
 - solution media effect, 459
- TDA
- diffusion coefficients, 457
 - FIDA, 450
 - hydrodynamic flow, 449
 - non-covalent interactions, dispersion measurements, 453
- Capillary breakup extensional rheometer (CaBER), 734
- Capillary electrophoresis (CE), 14, 440, 441
- Capillary electrophoresis frontal analysis (CE-FA), 447
- Capillary isoelectric focusing (cIEF), 457
- Capillary rheometers, 729, 739
- Capillary viscometry, 728, 738–739
- Carbamazepine, 80, 186
- CASTEP program, 308
- Celecoxib, 763
- Central nervous system (CNS), 801
- Cetirizine, 432
- Charge-coupled device (CCD), 9, 322, 524, 531
- Chemical force microscopy (CFM), 655
- Chemical ionization (CI), 255
- Chemometric analysis, 399
- Chromophores, 4
- Cilexetil, 759
- Circular dichroism (CD) spectroscopy
- absorbance, 228
 - absorption, BNF–224
 - amino acid alanine, 224
 - background spectrum, no subtraction of, 248
 - calibration and maintenance, 243–245
 - chirality, 224
 - circularly polarized light, 224
 - cuvettes and cell pathlength, 228–229
 - data acquisition, 247
 - instrumentation, 226–228
 - measurement at excessive HT, 247
 - in pharmaceutical sciences
 - advanced drug delivery systems, 239–241
 - biosimilar, development of, 235
 - insulin, 237–239
 - pH values, 235, 236
 - RIME, 241–242
 - synchrotron radiation, 242
 - thermodynamics, 236
 - protein structure
 - dialanine, 230
 - far UV and near UV CD spectroscopy, 232–234
 - native state, 230
 - quaternary structure, 231
 - secondary structure elements, 230, 231
 - tertiary structure, 230
 - unfolded state, 232
 - reference/baseline spectrum, 229
 - sample preparation, 246–247
 - secondary structure fits, overinterpretation of, 248
- Circularly polarized light (CPL), 224
- Classical least squares (CLS), 543, 561
- Cluster analysis, 561
- Coatl, 30
- Cogswell analyses, 735
- Coherent anti-Stokes Raman scattering (CARS), 21
- Coherent anti-Stokes Raman spectroscopy (CARS), 531
- Collision activated dissociation (CAD), 262
- Collisional quenching, 43
- Collision-induced dissociation (CID), 262, 277
- Column chromatography, 414

- Compendial dissolution models, 758
 Complementary metal oxide semiconductor (CMOS), 12
 Composite sensor array (CSA), 89
 Connes advantage, 148
 Contact mode, 652
 Continuous solvent area model, 326
 Contraction flow analysis, 734–735
 Conventional circular dichroism (cCD) spectrometers, 242
 Correlation coefficient (CV), 71
 Coulter principle, 690
 Counterfeit detection, 161
 Critical micelle concentration (CMC), 458, 758
 Critical quality attributes (CQAs), 89, 91
 Crystalline phonon vibrations, 534
 Crystallisation, 186–187
 Crystallographic Information File (CIF), 311
 Current correction method, 458
 Current good manufacturing practice (cGMP), 475
 Cyclodextrins, 457, 458
 Czemy-Tuner spectrograph, 148
- D**
- Debye models, 175
 Delta Epsilon, 227, 228
 Density functional theory (DFT), 182
 Desorption electrospray ionization (DESI) advantages, 631
 API in tablet, 636
 disadvantages, 631
 imaging resolution, 633
 mass range, 633
 solid–liquid extraction, 633
 Deuterated tri glycine sulphate (DTGS), 525
 Diclofenac sodium, 398
 DICVOL program, 301
 Dielectric spectroscopy, 376
 Differential centrifugal sedimentation (DCS), 688
 Differential scanning calorimetry (DSC), 390
 conventional DSC, 364–366
 hyper DSC, 367–368
 MTDSC, 366–367
 polymorph stability, 396
 power-compensation designs, 391
 purity determination, 396
 Diffractometers, 297
 Diffuse reflectance (DRIFT) spectroscopy, 67
 Diffusion weighted imaging (DWI), 617
- Digestion models
 complex physiologically relevant models
 DGM, 782–784
 TIM-1 model, 784–786
 LbDDS, 776
 pH-stat controlled *in vitro* lipolysis models
 calcium, 776
 experimental conditions, 779
in vivo - *in vitro* correlations, 778–781
 intestinal digestion, 776
 low pH and gastric digestion, 777
 microbial/animal-derived gastric lipases, 777
 pellet phase, 778
 recombinant HGL, 777
 processes
 bile secretions, 774
 drug absorption, 774
 excipients, 774
 gastric lipase, 774
 hydrolysis, 774
 intestinal lipid digestion, 774
 stomach and small intestine, 775
 tri- and di-acylglycerols, 774
 Dimethyldioctadecylammonium (DDA), 694
 Direct orthogonalization (DO), 76
 Direct standardization (DS), 76
 Discrete element modelling (DEM), 202
 Disk centrifugation, 689
 Dissolution models
 absorption module
 biphasic dissolution models, 763–765
 D/P models, 765–767
 equilibrium solubility, 754
 intestinal fluids, 753
 Nernst-Brunner/Noyes Whitney equation, 754
 pharmacopoeial dissolution models
 basket and paddle apparatus, 756–757
 DDS, 755
 flow-through apparatus, 757–758
 modified release dosage forms, 755
 oral dosage forms, 755
 QC and research and development purposes, 755
 reciprocating cylinder apparatus, 757
 physiologically relevant dissolution media, 758–759
 small volume dissolution models, 759–760
 Stokes-Einstein equation, 754
 transfer models, 761–763
 Double-beam UV-vis spectrophotometer, 7
 Dounce homogenizer, 805, 806

- Drug delivery system (DDS), 755
- Drug lipophilicity, 445
- Drug metabolism and pharmacokinetics (DMPK), 282
- Drug molecules, crystal structure of
 crystalline phase transitions, 184–185
 fundamental properties, polymorphism, 183–184
 identification, polymorphism, 177–178
 quantification, 178–181
 terahertz spectra, interpretation of, 181–183
- Drug polymorphism, 157
- Drug transport, 797–801
 ADME properties, 792
 barrier tissues, 792–794
 BBB (*see* Blood-brain-barrier (BBB))
 cell culture and tissue based *in vitro*
 models, 797–800
 hepatic models, 807–808
in vitro models, 792
 paracellular *vs.* transcellular pathways, 792
 renal models, 809–810
 simple transport kinetics, 794–795
 transport kinetics, 795–796
- Dry powder inhalers (DPI), 660, 703
- Dynamic gastric model (DGM), 782
- Dynamic light scattering (DLS), 457, 475, 659, 679, 693–696
- Dynamic mechanical analysis (DMA), 376
- E**
- Eddy diffusion, 423
- Efflux transporters, 796, 808
- Elastic scattering, 530
- Electrical Low Pressure Impactor (ELPI), 711
- Electrochemical AFM (EC-AFM), 654
- Electrochromatograms, 448
- Electromagnetic radiation, 171
- Electron capture dissociation (ECD), 262
- Electron ionization (EI), 255
- Electron microscopy, 571
 electron beam generation and focus, 500
 field emission, 501
 image generating data, 500
 TEM, 502–508
 acceleration voltage, 502
 application, pharmaceutical formulation research, 504–508
 colloidal drug carrier systems
 voltages, 502
 sample preparation and investigation, 502–504
 thermionic emission, 500
- Electron transfer dissociation (ETD), 262
- Electroosmotic flow (EOF), 442
- Electrospinning, 745
- Electrospray ionization (ESI), 257–258
- ElectroSpray Ionization Mass Spectrometry (ESI-MS), 443
- Electrostatic force microscopy (EFM), 654
- Energy dispersive X-ray (EDX) spectrometry, 513, 516
- Enthalpy of solution, 397–398
- Environmental scanning electron microscopy (ESEM), 512–513
- Epidermal growth factor receptor (EGFR), 575
- Erlotinib, 575
- Ethosuximide (ESM), 555
- Ethyl phenyl carbonate, 19, 20
- Etravirine, 377
- European Pharmacopoeia (Ph.Eur.), 755
- Everhart-Thornley detector, 509
- Extensional rheology
 biaxial and planar flow, 735–736
 biaxial extension, 730
 Hencky strain and Hencky strain rate, 730
 measurements (*see also* Shear rheology)
 planar extension, 730
 polymer industry, 732
 strain hardening polymers, 732
 streamlines, 730
 Trouton's ratio, 731
 uniaxial extension, 730
 uniaxial flow
 contraction flow analysis, 734–735
 filament thinning experiments, 734
 miniature scale, testing, 735
 rotating drum devices, 733
- Extracted ion chromatogram (EIC/XIC), 266
- Eysenhardtia polystachya*, 30
- F**
- Fast Fourier transform (FFT), 87, 111, 611
- Fast Low Angle Shot (FLASH)
 sequence, 608
- Fasted State Simulated Intestinal Fluid (FaSSIF), 759
- Fatty acids (FAs), 774
- Felgett advantage, 149, 166
- Felodipine, 381
- Fenofibrate, 757, 781
- Fermi resonance, 65
- Fiber optic probe spectrophotometers, 10–12
- Field-flow fraction (FFF), 468
- Filament stretching rheometer (FISER/FSR), 734

- Film coating
 coating uniformity, 198–200
 functional coatings, 200–204
 in-line sensing, 206–207
 process sensors, calibration of, 204–205
 TPI technique, 196
- Fine particle dose (FPD), 702, 710
- Flory-Huggins lattice based theory, 381
- Flow calorimetry, 393
- Flow field flow fractionation (FFF), 477
- Flow induced dispersion analysis (FIDA), 450
- Flow-through apparatus, 756–758
- Flufenamic acid, 190
- Fluid bed dryer (FBD), 89, 108
- Fluid bed granulation (FBG), 108–109
- Fluorescence, 144–146, 443
 emission, 38, 50
 excitation, 40, 50
 imaging, 493
 lifetime, 36, 51
 microscopy, 45, 572
 phenomenon
 Palo Azul, 30
 polarization, 42
 quantum yield, 37
 quinine sulfate, 31
 Stokes shift, 31
- Fluorescence lifetime image (FLIM), 52
- Fluorescence spectroscopy
 absorption and Beer-Lambert law, 34
 1,8-ANS/serum albumins, interaction of, 53
 emission, 38, 50
 excitation, 40, 50
 lifetime, 36, 51
 markers and reporters, 46–48
 polarization, 42
 quantum yield, 37
 quenching, 43
- Fluorimeter, refractive index (RI) detector, 469
- Fluoroalkylsilane (FAS), 665
- Fluorometers, 35, 48
- Fluorophores, 37
- Focal plane array (FPA), 524, 529
- Focus beam reflectance measurements (FBRM), 87
- Focused beam reflectance measurements (FBRM), 109
- Food and drug administration (FDA), 801
- Förster resonance energy transfer (FRET), 44
- Fourier self deconvolution (FSD), 69, 97
- Fourier transform (FT), 148–149, 531
- Fourier transform infrared (FTIR)
 mAb formulations, 99–102
 polymeric delivery systems, 102–103
 secondary structural analysis, 96
- Fourier transform infrared-photoacoustic spectroscopy (FTIR-PAS), 66
- Fourier transformation (FT), 525
- Franck-Condon principle, 32
- Fraunhofer approximation, 705
- Fraunhofer theory, 684
- Freeze fracture technique, 516
- Frequency domain fluorometry, 53
- Frequency domain method, 51
- Full width of half height (FWHM), 97
- G**
- Gabapentin polymorphs, 184
- Gas chromatography (GC), 89, 368
- Gas chromatography coupled to mass spectrometry (GC-MS), 264
- Gas perfusion calorimetry, 393, 400, 403
- Gastro-intestinal (GI) tract, 742, 755
- G-coupled protein receptors (GPCR), 355
- Geometric standard deviation (GSD), 710
- Gleditsia triacanthos*, 745
- Global molecular mobility, 375
- Global optimisation approach, 307–308
- Goniometer, 322
- Gordon-Taylor (G-T) equation, 374
- Grazing incidence small angle x-ray scattering (GI-SAXS), 354
- Green fluorescent protein (GFP), 47–48
- Griseofulvin, 162, 164
- GV150013X, 759
- H**
- Hahn spin echo sequence, 599
- Hancock-Sharp equation, 396
- Harmonic oscillator approximation, 62
- Heat conduction calorimetry, 391–392, 405
- Hierarchical cluster analysis (HCA), 576
- High performance liquid chromatography (HPLC), 200, 413
 animal experiments, 432
 5-ASA, 431
 components of, 424
 detectors, 429
 drug substances and drugs, analysis of, 430
 mobile phase, 425
 pump, 426
 sample injection, 426
 separation column, 426–428
 troubleshooting, 433

- High shear wet granulation (HSWG), 109–110
 High throughput techniques, 345–346
 Hollow fiber FFF (HF5), 469
 Hooke's law, 722
 Horiba LabRAM ARAMIS system, 555
 Hot-melt extrusion (HME), 112
 Human gastric lipase (HGL), 777
 Human serum albumin (HSA), 53
 Hyaluronic acid, 746
 Hydro fluoroalkanes (HFA), 703
 Hydrocolloids, 744
 Hydrodynamic diameter, 681
 Hydrogels, 744
 Hydrogen/deuterium exchange mass spectrometry (HDX-MS), 278–281
 Hydroxyethyl starch (HES), 479
 Hydroxypropyl methylcellulose (HPMC), 377, 565, 592, 614
- I**
 Ice calorimeters, 391
 Imidafenacin, 79
 Indirect hard modeling (IHM), 88
 Indomethacin, 190, 377
 Inductively Coupled Plasma Mass Spectrometry (ICP-MS), 443
 Inelastic scattering phenomenon, 140
 Infrared laser ablation metastable-induced chemical ionization (IR-LAMICI), 636
 Infrared (IR) spectroscopy, 14, 62
 Inhalation profile, 713
 Inner filter effect, 36
 In-source decay (ISD), 263, 277
 Institute for Food Research (Norwich, UK), 782
 Insulin, 237–239
 Intestinal cell culture models, 800–801
 Intra-tablet coating uniformity, 201
In vivo - in vitro correlations (IVIVC), 758, 778
 Irbesartan, conformational disorder, 184
 Isothermal microcalorimeters (IMC)
 amorphous content quantification, 400
 dosage forms, 402–404
 drug stability, 398–399
 drug-excipient compatibility screening, 395–396
 enthalpy of solution, 397–398
 in vivo applications, 404–405
 kinetics, 391
 pharmaceutical samples, measurement of, 390
 polymorph stability, 397
 preformulation characterisation, 395
 purity determination, 396
 thermodynamics, 391
 time-dependent phase transitions, 390
 ubiquity of heat, 405
 Isothermal titration calorimetry (ITC), 393, 404
- J**
 Jacquinet advantage, 148, 166
 Johari-Goldstein (JG) -relaxation, 187
- K**
 Karl Fischer titration (KFT), 89
 Kelvin probe force microscopy (KPFM), 654
 Kerr-gating, 145
 K nearest neighbours (KNN), 71
 Kolliphor[®], 781
- L**
 Laboratory X-ray powder diffraction instrumentation, 305
 alignment, 300
 crystal structure determination (*see* Structure determination from powder diffraction (SDPD))
 indexing, 301–303
 Pawley refinement, 304
 phase quantification, 311
 phase transitions, 311
 physical form identification, 300–301
 PSD, 297
 radiation source, 296
 refined crystal structure, final check on, 311
 reflection geometry, 297–298, 300
 scintillation-based point detector, 297
 space group identification, 303–304
 transmission geometry, 298, 300
 Laboratory X-ray scattering instruments, 341
 Labrasol, 784
 Lambert-Beer's law, 4–6, 24
 Lanthanum hexaboride (LaB₆), 501
 Larmor precession frequencies, 601
 Laser ablation inductively couple plasma mass spectrometry (LA-ICP-MS), 633, 642
 Laser diffraction (LD), 703, 704
 Latent variables (LV), 70
 Lateral force microscope (LFM), 652

- Light and electron microscopy. *See also*
- Electron microscopy
 - optical microscopy, 493–499
 - general principles of, 493–496
 - pharmaceutical analysis, 498–500
 - special techniques, 496–498
 - pharmaceutical formulation research, 492
 - SEM
 - accelerating voltage, 508
 - electron beam-specimen interactions, 510–512
 - energy dispersive X-ray spectrometry, 513–514
 - ESEM, 512–513
 - Everhart-Thornley detector, 509
 - Faraday cage, 510
 - pharmaceutical application, 514–516
 - sample preparation, 512
 - secondary electrons, 509
 - surface imaging, 508
 - three-dimensional” grayscale images, 508
- Light emitting devices (LEDs), 49
- Light-emitting diode (LED), 67
- Limit of detection (LOD), 283
- Limit of quantitation (LOQ), 283
- Linear discriminant analysis (LDA), 71
- Linear image signature (LIS), 561
- Linearly variable filter (LVF), 68
- Lipolysis model, 778
- Lipopolysaccharide (LPS), 666
- Liposomes, 54
- Liquid chromatography (LC)
 - calibration standards, 435
 - clinical trials and bioanalysis, 433–435
 - detectors, 429
 - drug discovery process, 430
 - drug formulation and stability, 430–432
 - eddy diffusion, 423
 - log P and D values, determination of, 430
 - longitudinal diffusion, 423
 - mass transfer, 423
 - pKa values, 430
 - precolumn, 435
 - retention, 417–418, 422
 - sample preparation, 432, 434
 - separation
 - analytes, partition of, 414
 - efficiency, 419–420, 422
 - mobile phase, 414
 - resolution, 420–421
 - selectivity, 419
 - stationary phase, 414
 - theory of partition, 415–417
 - validation, 435
 - van Deemter equation, 423–424
- Liquid chromatography coupled mass spectrometry (LC-MS), 265–266
- Liquid extraction surface analysis mass spectrometry, 643
- Liquid-liquid extraction (LLE), 266, 286–287
- Liquid metal ion guns (LMIG), 632
- Lissajous analysis, 372
- Localised thermal analysis (LTA), 368
- Locally weighted regression (LWR), 71
- Long chain self-microemulsifying drug delivery systems (LC-SMEDDS), 778
- Low angle laser light scattering (LALLS), 705
- Lubricated squeezing flow, 736
- Luminescence
 - definition, 29
 - fluorescence phenomenon, 30, 31
 - phosphorescence phenomenon, 31
- Lyotropic liquid crystals (LLCs), 345
- M**
- Madin-Darby canine kidney (MDCK), 800
- Magnetic force microscopy (MFM), 654
- Magnetic resonance imaging (MRI)
 - chemical and spatial information, 592
 - chemical shift imaging techniques, 592
 - HPMC, 592
 - NMR
 - origins of, 594
 - spin-lattice relaxation, T_1 , 597–598
 - spin-spin relaxation, T_2 , 599
 - one dimensional image profiling
 - integration, 602
 - k -space formalism, 602–603
 - Larmor frequency, 601
 - relaxation effects, 602
 - solid dosage form pharmaceutical research, 616–622
 - API, 623–624
 - gradient echo (GE) imaging, 609
 - k -space raster, 607
 - nuclear spin-density, 606
 - phase shift velocity imaging, 620
 - quantifying mass transport, 616–622
 - quantitative spin echo, 613–615
 - self-diffusion, 617
 - spin system excitation, 606
 - standard imaging protocols, 606
 - spatial information, 592
 - two-dimensional slice selective imaging, 605

- Main and Interactions of Individual Principal Components Regression (MIPCR), 79
- Malvern Spraytec, 705
- Mannitol, 78
- Mass median aerodynamic diameter (MMAD), 710
- Mass spectrometry (MS), 429, 483
- analyte, 255
 - array collectors, 260
 - capillary electrophoresis, 265
 - data representation, 266–268
 - drug development, 268
 - drug discovery progress, 254
 - electron multipliers, 261
 - Faraday cups, 261
 - gas chromatography, 264
 - hard ionization
 - APCI, 256
 - chemical ionization, 255
 - electron ionization, 255
 - ionization techniques, application range of, 258
 - ion-to-photon detectors, 261
 - liquid chromatography, 265–266
 - mass analyzers
 - characteristics of, 260
 - orbitrap, 259
 - quadrupole, 258
 - resolution, 260
 - 3D/Paul Ion trap, 259
 - TOF, 258
 - microchannel plate detectors, 261
 - point-ion-collectors, 260
 - protein and peptide pharmaceuticals
 - electrospray ionization, 272
 - MALDI, 272
 - mass spectra, interpretation of, 273–276
 - primary structure, 272, 273
 - tandem MS, 276–277
 - quantitative LC-MS, 282–284
 - sample preparation
 - liquid/liquid extraction, 286–287
 - protein precipitation, 284–285
 - solid-phase extraction, 285
 - turbulent flow chromatography, 286
 - sensitivity and low detection limits, 254
 - small molecule drugs
 - chemical synthesis, monitoring of, 269–270
 - drug delivery and stability, 270–271
 - mass spectrum interpretation, 268–269
 - soft ionization
 - ESI, 257–258
 - MALDI, 256–257
 - tandem mass spectrometry (*see* Tandem mass spectrometry (MS/MS))
- Mass spectrometry imaging (MSI)
- advantages, 630
 - applications, 630
 - comparative performance of, 631
 - DESI (*see* Desorption electrospray ionization (DESI))
 - LAICPMS imaging, 634
 - MALDI (*see* Matrix assisted laser desorption ionization (MALDI))
 - ToF-SIMS (*see* Time-of-flight secondary ion mass spectrometry (ToF-SIMS))
- Matrix assisted laser desorption ionization (MALDI), 256–257
- advantages, 631, 633
 - API
 - array analysis, 637
 - in tablet, 635, 636
 - biological and drug molecules, label-free imaging in, 640–641
 - disadvantages, 631
 - mouse kidney, 3D reconstruction of, 644
- Mean dissolution time (MDT), 203
- Meclofenoxate hydrochloride (MF), 398
- Medium chain self-microemulsifying drug delivery systems (MC-SMEDDS), 778
- Melting point depression approach, 381
- Mercury cadmium telluride (MCT), 525
- Mesoscale drug delivery systems
- high throughput techniques, 345–346
 - LLCs, 345
 - spatially resolved, 349–350
 - time resolved studies, 347–349
 - TLC, 345
- Micellar EKC (MEKC), 456
- Michelson interferometer, 148, 525
- Micro-and nanosized particles
- bimodal populations measurements
 - bimodal, 693–696
 - light scattering based particle sizing
 - DCS DCS, 688
 - DLS DLS, 679
 - laser diffraction, 684–685
 - NTA, 686
 - liposomes, DLS and NTA measurement of lipo, 696–697
 - measurement techniques application, 677–679
 - pulse sensing particle sizing methods
 - coulter counter, 690
 - TRPS TRPS, 690
- Microbead force spectroscopy (MBFS), 666
- Microcrystalline cellulose (MCC), 212

- Micro-electro-mechanical systems (MEMS), 68, 735
- Microemulsion EKC (MEEKC), 456
- Micro-thermal analysis (μ TA), 369
- Micro-volume spectrophotometer, 9, 10
- Mid-infrared (MIR) spectroscopy
 absorbance, 62–63
 active pharmaceutical ingredient
 crystallization, 87–88
 reaction monitoring, 86–87
 ATR-IR, 528
 backscattering, transmission and ATR, 527
 freeze-drying process, 116
 FT technique, 65–66
 incandescent silicon carbide/synchrotron, 525
 interferogram signal, 525
 near-field MIR, 528–529
 numerical aperture, 525
 pharmaceutical solid-state characterization
 amorphous/crystalline ratio, 84
 cocrystal characterization, 82–83
 polymorph screening and
 quantification, 80–81
 water content and hydration state
 determination, 79–80
 protein formulation development
 mAb formulations, 99–102
 polymeric delivery systems, 102–103
 secondary structural analysis, 96–98
 sampling techniques
 ATR setup, 67
 DRIFT spectroscopy, 67
 transmission, 66
 signal processing, 69
 skin profiling, 119
 solid dispersions, 91–92
 transitions, 525
 transmission, 528
- Mie theory, 683, 684, 689, 705
- Mirror image rule, 39
- Miscibility, 381
- Modulated temperature differential scanning
 calorimetry (MTDSC), 366–367
- Molar Circular Dichroism, 227
- Monochromatic incident radiation, 296
- Monoclonal antibodies (mAb), 664
- Monoglycerides (MAG), 774
- Moving Block Standard Deviation (MBSD), 105
- Moving window partial least squares
 regression (MWPLSR), 119
- Mucins, 743
- Multi-angle laser light scattering (MALLS)
 detector, 469, 471
- Multiphoton excitation, 33
- Multiple cure resolution (MCR), 156, 544
- Multiple linear regression (MLR), 152
- Multiple reaction monitoring (MRM), 263
- Multiplicative scatter correction (MSC), 70, 540
- Multivariate curve resolution (MCR), 71,
 561, 639
- Multivariate statistical process control
 (MSPC), 81
- N**
- Nanoparticle tracking analysis (NTA), 686
- Nanoparticles (NPs), 659
- Nanostructured lipid carriers (NLCs), 479
- Near infrared (NIR) spectroscopy
 absorption bands
 anharmonicity, 64–65
 combination bands, 64, 65
 Fermi resonance, 65
 overtone band, 64, 65
 active pharmaceutical ingredient
 crystallization, 88
 drying, 89–90
 reaction monitoring, 87
 blend monitoring
 data processing strategy, 105
 qualitative methods, 105–106
 quantitative approaches, 106–108
 sample size, 105
 sampling points, 104
 coating process monitoring, 114–116
 drug dissolution, 91, 94–95
 freeze-drying process, 116–117
 hot-melt extrusion, 112
 instrumentation, 67–68
 laboratory analyzers, 68
 medical monitoring, 118
 multiple CQAs, simultaneous
 determination, 95
 multivariate data analysis
 data pretreatments, 70
 regression methods, 71
 supervised classification, 71
 unsupervised classification, 70
 particle size determination, 92
 pelletization, 112–113
 pharmaceutical solid-state characterization
 amorphous/crystalline ratio, 84, 85
 cocrystal characterization, 83
 polymorph screening and
 quantification, 81–82
 water content and hydration state
 determination, 77–79
 process analyzers, 68

- protein formulation development
 - mAb formulations, 102
 - polymeric delivery systems, 103
 - secondary structural analysis, 98–99
 - qualitative analysis
 - correlation methods, 72
 - distance-based supervised methods, 72
 - supervised classification algorithms, 72
 - threshold value, 73
 - variable selection, 72
 - quantitative analysis
 - β -expectation tolerance intervals, 76
 - calibration maintenance, 76
 - calibration samples, 74
 - calibration transfer, 76
 - multivariate calibration modeling, 74
 - NAS, 75
 - PCP, 75
 - PCR/PLS algorithms, 75
 - reference method, 74
 - representative calibration sample set, 73–74
 - RMSEC, RMSECV, RMSEP, 75
 - sampling strategy, 73
 - spectral resolution, 73
 - TK approach, 76
 - roller compaction, 110–111
 - scatter effects, 65
 - solid dispersions, 91, 92
 - tablet hardness testing, 91, 93–94
 - tableting and capsule filling, 113–114
 - tissue analysis, 119
 - wet granulation
 - fluid bed granulation, 108–109
 - high shear wet granulation, 109–110
 - subphases, 108
 - twin screw granulation, 110
 - Nearly constant losses (NCL), 187
 - Nernst-Brunner equation, 754
 - Net analyte signal (NAS), 75
 - New chemical entity (NCE), 440
 - Next Generation Impactor (NGI), 708
 - Nifedipine, 381
 - Nitrofuantoin, 499
 - Nitrofurantoin, 80
 - Non-contact mode, 652
 - Non-Hodgkin's lymphoma (NHL), 664
 - Non-uniform fast Fourier transforms (NUFFT), 612
 - Normal absorbance spectroscopy, 229
 - Noyes Whitney equation, 742, 754
 - Nuclear magnetic resonance (NMR), 432, 591
 - Numerical aperture (NA), 525
- O**
- Octadecylsilylsilica (ODS), 427
 - Octadecyltrichlorosilane (OTS), 665
 - Oil immersion technique, 493
 - Optical coherence tomography (OCT), 197
 - Optical parametric oscillator (OPO), 556
 - Optical particle counters (OPCs), 706–707
 - Oralmucosal drug delivery, 745
 - Organic cation transporters (OCTN), 809
 - Orthogonal signal correction (OSC), 70
- P**
- Paddle apparatus, 756–757
 - Palo Azul, 30
 - Paracetamol, 190, 377
 - Partial least squares (PLS), 153, 543, 561
 - Partial least squares discriminant analysis (PLS-DA), 71
 - Partial least squares regression (PLSR), 71, 75
 - Particle deposition mechanisms, lung, 702
 - Pawley refinement, 304
 - Peak capacity (PC), 420
 - PeakForce Tapping[®] (PFT), 653
 - Peptide mass finger printing (PMF), 273
 - Perrin-Jablonski diagram, 32
 - Pharmacopoeial dissolution models
 - basket and paddle apparatus, 756–757
 - DDS, 755
 - dosage forms, 755
 - flow-through apparatus, 757–758
 - QC and research and development purposes, 755
 - reciprocating cylinder apparatus, 757
 - Phase contrast technique, 496
 - Phasor analysis, 51
 - Phospholipids (PL), 758, 774
 - Phosphorescence, 29
 - Photocalorimeter, 403
 - Photoconductive AFM (pcAFM), 654
 - Photodiode array (PDA) UV-vis spectrophotometer, 9
 - Photo elastic modulator (PEM), 226
 - Photomultipliers, 49
 - Photo multiplier tube (PMT), 226
 - Photon correlation spectroscopy (PCS), 679
 - Piezoelectric ceramic scanner, 650
 - Planck's constant, 4
 - Polarization microscopy, 496
 - Polarizers, 49
 - Polydispersity index, 684
 - Polyethylene glycol (PEG), 566
 - Polyethylenimine (PEI), 479

- Poly(lactic acid-co-glycolic acid) (PLGA), 659
 Poly(lactic-co-glycolic acid) (PLGA), 553
PolySNAP program, 300
 Polysorbate 80, 755
 Position-sensitive detector (PSD), 297
 Postnova, 471
 Powder X-ray diffraction (PXRD), 296
 crystal structure determination, 294, 295
 cyheptamide form II, pattern of, 294, 295
 laboratory-based PXRD (*see* Laboratory X-ray powder diffraction instrumentation)
 peak intensities, 295
 peak positions, 294
 synchrotron beamlines, 312
 X-ray photon flux, 312
 Power-compensation calorimetry, 391, 405
 Pressurized metered dose inhalers (pMDIs), 703
 Principal component analysis (PCA), 70, 105, 151, 543, 561, 643
 Principal component regression (PCR), 70, 71, 152–153
 Principal components (PC), 70
 Principal Component Scores Distance Analysis (PC-SDA), 105
 Principal components regression (PCR), 75
 Principle of particle collection, 709
 Process analytical technology (PAT), 212
 6-Propionyl-2-dimethylaminonaphtalene (PRODAN), 39
 Protein crystallography, 344
 Proton-coupled amino acid transporter (PAT1), 799
Pseudomonas aeruginosa, 665
 Pseudo-stationary phase, 445
 Pulsed (magnetic) field gradient spin echo (PFG-SE), 617
 Pure-component projection (PCP), 75
 Push-pull osmotic system (PPOS), 200
- Q**
- Quadratic discriminant analysis (QDA), 71
 Quadrupoles, 259
 Quantitative Nanomechanical Mapping (QNM[®]), 654
 Quasielastic light scattering (QELS), 679
 Quinine sulfate, 31
- R**
- Rabinowitch correction procedure, 729
 Raman peak, 50
 Raman scattering, 141
 Raman spectroscopy
 chemometrics
 MCR, 156
 pattern recognition, 151
 PCA, 151
 PCR, 152–153
 PLS, 153
 SIMCA, 155
 unsupervised and supervised techniques, 151
 coherent Raman, 531–533
 counterfeit detection, 161
 experimental methods
 dispersive systems, 147–148
 FT systems, 148–149
 spectral correction, 149–150
 in vivo drug delivery, 159
 near-field effects, 533
 new technologies and experimental protocols
 low frequency Raman spectroscopy, 162–163
 SORS, 163–165
 spatial heterodyne Raman spectroscopy, 166
 transmission Raman, 165
 Raman scattering theory, 140
 ranitidine hydrochloride polymorphism, 157–159
 spontaneous, 530–531
 Ram-Lak filter, 612
 Ranitidine hydrochloride, 157–159
 Raster imaging correlation spectroscopy (RICS), 45
 Rayleigh scattering, 49, 140, 162, 530
 Reactive oxygen species (ROS), 662
 Reciprocating cylinder apparatus, 756, 757
 Refractive index (RI), 241
 Refractive index matched emulsion (RIME) method, 241–242
 Relative humidity (RH), 393
 Relative vapour pressure (RVP), 393
 Reversed phase chromatography, 426
 Rheology, pharmaceutical science
 API, 720
 definition, 719
 dosage forms and biological samples, extensional rheology of, 744–746
 extensional (*see* Extensional rheology)
 shear (*see* Shear rheology)
 Rhizopus Oryzae (ROL), 784

- Rietveld refinement
 chemical restraints, 310
 molecular organic crystal structures, 310
 phase quantification, 311
 programs, 309
 rigid-body, 310
- Rituximab, 664
- Root mean squared error of calculation (RMSEC), 154
- Root mean squared error of calibration (RMSEC), 75
- Root mean squared error of cross validation (RMSECV), 75
- Root mean squared error of prediction (RMSEP), 75, 154
- Red blood cells (RBCs), 663
- S**
- Sanfetrinem, 759
- Scanning capacitance microscopy (SCM), 654
- Scanning electron microscopy (SEM), 474, 492, 500, 558, 703, 707
- Scanning force microscope (SFM), 650
- Scanning probe microscopes (SPM), 650
- Scanning spreading resistance microscopy (SSRM), 654
- Scanning thermal microscopy (S_{Th}M), 654
- Scanning tunnelling microscope (STM), 533, 650
- Science-based calibration (SBC), 116
- Scintillation-based point detector, 297
- Searching combination moving window partial least squares (SCMWPLS), 119
- Second harmonic generation (SHG), 532, 577
- Sedimentation method, 689
- Selected reaction monitoring (SRM), 263, 266
- Self-assembled monolayers (SAMs), 655
- Self-emulsifying drug delivery system (SEEDS), 783
- Self micro-emulsifying drug delivery system (SMEDDS), 783
- Self-modelling curve resolution (SMCR), 561
- Self nano-emulsifying drug delivery system (SNEDDS), 783
- Sentmanat extensional rheometer (SER), 733
- Shear rheology
 biological samples, 742
 capillaries, 720
 rheometers, 729, 739
 viscometry, 728, 738–739
 commercial applications, 741
 cone-and-plate and concentric cylinder tools, 720
 controlled rate type instrument, 721
 controlled stress type instrument, 721
 creep and relaxation measurements, 727
 creep measurements, 738
 deformations, 720
 dosage forms, 740–742
 drum devices rotation, 740
 gelling agents, 741
 geometry, 720, 721
 in situ gelling systems, 741
 lipid droplets, heteroaggregation of, 741
 lubricated squeezing flow, 740
 measuring cells, 722
 non-Newtonian liquids, 723–724
 oscillatory measurements, 725
 right geometry, 737
 rotational type instruments, 722
 steady shear measurements, 737–738
 uniaxial extension tests, 739
- Shepp-Logan filter, 612
- Shifted excitation Raman difference spectroscopy, 146
- Simvastatin, 190
- Single-beam UV spectrophotometer, 7
- Single-crystal X-ray diffraction (SXRD), 293
 absolute structure
 differences and quotients, 329
 Flack parameter, 328
 Friedel pairs, intensities of, 327
 non-centrosymmetric structures, 326–327
 control and data processing software, 323
 crystal lattice, geometry of, 316, 319
 crystal structure, 319–321
 data collection strategy
 centrosymmetric diffraction pattern, 333
 completeness, 333
 data collection time, 334
 diffraction pattern, 332
 redundancy, 333
 resolution, 332
 data processing, 334–335
 detectors, 322
 diffracted intensities, 317, 319
 displacement parameters, 318
 goniometer, 322
 H atoms, 323–324
 metric symmetry, 319
 microfocus source, 322
 Mo/Cu radiation, 331
 non-stoichiometry and disorder, 324–326
 sealed tube, 321
 small drug molecules, 315
 space group, 319
 structure checking procedures, 335–336
 temperature, 331

- Single-molecule force spectroscopy (SMFS), 654
 - Single wall carbon nanotubes (SWNTs), 480
 - Size exclusion chromatography (SEC), 469
 - Small angle x-ray scattering (SAXS), 340, 349
 - A-SAXS, 352–354
 - biological macromolecules, 344
 - grazing incidence, 354
 - liposome drug delivery systems, 343
 - mesoscale structures
 - micellar systems, 343
 - protein crystallography, 344
 - SBDD, 344
 - self nanoemulsifying and microemulsion drug delivery systems, 343
 - Sodium lauryl sulphate (SLS), 755, 764
 - Soft independent modeling of class analogies (SIMCA), 70
 - Solid lipid microparticles (SLMs), 556
 - Solid lipid nanoparticles (SLNs), 479
 - Solid-phase extraction (SPE), 266, 285
 - Solute carrier family (SLC), 792
 - Solution calorimetry, 393
 - amorphous content quantification, 399–400
 - drug formulations, 403
 - enthalpies of solution, 398
 - Sophora japonica*, 745
 - Source for circular dichroism (SRCD), 242
 - Spatially offset Raman scattering (SORS), 163–165
 - Spatially offset Raman spectroscopy (SORS), 161
 - Spectrophotometric detectors, 429
 - Spraying process, 744
 - Sputum, 743
 - Standard normal variate (SNV), 70, 540
 - Staring array, 524
 - Static light scattering (SLS), 484
 - Static quenching, 43
 - Stejskal-Tanner equation, 617
 - Stern-Volmer equation, 43
 - Stimulated Raman scattering (SRS), 560
 - Stimulated Raman spectroscopy (SRS), 531
 - Stokes-Diameter, 681
 - Stokes-Einstein equation, 686, 742, 754
 - Stokes lines, 142
 - Stokes scattering, 530
 - Stokes shift, 31
 - Strickler-Berg equation, 37
 - Structure-based drug design (SBDD), 344
 - Structure determination from powder diffraction (SDPD), 309
 - data collection, 306
 - global optimisation approach, 307–308
 - modified direct methods, 307
 - Rietveld refinement (*see* Rietveld refinement)
 - structure solution, 306, 309
 - Sum frequency generation (SFG), 532
 - Super resolution stimulated emission depletion (STED), 667
 - Support vector regression (SVR), 71
 - Surface-enhanced Raman spectroscopy (SERS), 533
 - Surface potential microscopy (SPoM), 654
 - Sympatec Inhaler module, 705
 - Sympatec Sprayer, 705
 - Synchrotron radiation (SR), 242
 - Synchrotron X-ray scattering, 341
- T**
- Tandem mass spectrometry (MS/MS)
 - application of, 263
 - full scan mode, 263
 - ion activation, 262–263
 - multiple reaction monitoring, 263
 - neutral loss scanning, 263
 - parent ions, 261
 - precursor ion scanning, 261, 263
 - product ion scanning, 261, 263
 - protein and peptide pharmaceuticals, 276–281
 - selected reaction monitoring, 263
 - in space, 261
 - in time, 262
 - triple quadrupole, 261
 - Tapping Mode[®], 652, 654
 - Taylor dispersion analysis (TDA), 440, 451
 - Terahertz electric field peak strength (TEFPS), 194
 - Terahertz interface index (TII), 194
 - Terahertz pulsed imaging (TPI), 191, 562
 - Terahertz radiation, 171–174
 - Terahertz spectroscopy, 534–536
 - Terahertz technology
 - chemical imaging, 207–208
 - tablet microstructure
 - cracks and delamination, 210–211
 - disintegration testing, 212–213
 - porosity, 211–212
 - tablet density/hardness, 209–210
 - terahertz imaging, 195–207
 - film coating (*see* Film coating)
 - instrumentation, 195
 - measurement principle, 191

- terahertz radiation, pharmaceutical analysis, 171–174
 - terahertz spectroscopy, 177–185
 - amorphous drugs below T_g, 187–190
 - amorphous materials, 185–187
 - dielectric relaxation processes, 175
 - drug molecules (*see* Drug molecules, crystal structure of)
 - molecular interactions, 174
 - optical properties, 175
 - VDOS, 174
 - Terahertz time-domain spectroscopy (THz-TDS), 173
 - Thermal analysis
 - differential scanning calorimetry, 363
 - pharmaceutical raw materials
 - amorphous drugs, 376–377
 - polymer blends, 377–378
 - polymers and lipidic excipients, 377
 - physical and chemical phenomena
 - crystallisation, 371
 - dehydration and decomposition, 376
 - glass transition, 372–374
 - molecular mobility, 375
 - polymorphic transformation, 371–372
 - structural relaxation, 375–ENF
 - scanning probe based thermal analysis, 368–370
 - semi-solid and liquid dosage forms, 383–384
 - solid dosage forms
 - amorphous solid dispersions, 379
 - crystallisation tendency, 379
 - drug-excipient miscibility estimation, 381–382
 - micro-scale drug distribution uniformity assessment, 382–383
 - moisture-induced instability, 380
 - physical stability of, 378
 - quantitative analysis of crystallinity, 379–380
 - TGA (*see* Thermogravimetric analysis (TGA))
 - Thermal decoupling process, 188
 - Thermogravimetric analysis (TGA), 368
 - Thermotropic liquid crystal (TLCs), 345
 - Throat model, 713
 - Tikhonov regularization (TK), 76
 - Time-gated detection schemes, 172
 - Time-of-flight (TOF), 258, 710–711
 - Time-of-flight secondary ion mass spectrometry (ToF-SIMS)
 - advantages, 631
 - API, 634
 - crystal/powder mixtures and coatings (*see* Coatings)
 - micro-array analysis, 638, 639
 - stent coating, 3D reconstruction, 637
 - in tablet, 636, 637
 - disadvantages, 631, 632
 - Tip-enhanced Raman spectroscopy (TERS), 533
 - TOPAS program, 301
 - Topography and recognition imaging (TREC), 654
 - Torsional resonance (TR) Mode[®], 653
 - Total ion current chromatogram (TIC), 266–268
 - Transition temperature mapping (TTM) technique, 370
 - Transmission electron microscopes (TEMs), 54, 474, 492, 500, 556
 - Transmission Raman spectroscopy, 165
 - Transretinol, 159
 - Triacetin, 396
 - Triacylglycerides (TAG), 774
 - Tributyryn unit (TBU), 780
 - Troglitazone, 759
 - Trouton's ratio, 731
 - Tunable resistive pulse sensing (TRPS), 690
 - Turbulent flow chromatography (TFC), 286
 - Twin screw granulation (TSG), 110
 - Two-dimensional (2D) FT-IR spectroscopy, 66
 - Two photon excited fluorescence (TPEF), 532, 577
- ## U
- Ultrahigh performance liquid chromatography (UHPLC), 414
 - animal experiments, 432
 - pressure limit, 426
 - separation column, 428
 - troubleshooting, 433
 - Ultra small angle X-ray scattering (USAXS), 342
 - Ultraviolet (UV) imaging
 - CMOS sensor chips, 12
 - components of, 12
 - drug diffusion and release, 24
 - drug dissolution
 - lidocaine, 22–23
 - Sirius SDI UV imaging instrument, 23
 - solid forms, ranking of, 24
 - theophylline, 23
 - wavelength range, 12
 - with in situ Raman spectroscopy, 23, 24

- Ultraviolet-visible (UV-vis)
 spectrophotometry, 24, 469
 CCD spectrophotometers, 9
 components, 6
 dissolution testing, 21
 double-beam spectrophotometer, 7
 equilibrium constants and complexation, 18
 kinetics and reaction monitoring, 18
 Lambert-Beer's law, 4–6
 light, 3
 micro-volume spectrophotometer, 9
 PDA spectrophotometers, 9
 pK_a values, 16–18
 qualitative analysis, 12–14
 quantitative analysis, 15
 single beam spectrophotometer, 7
 UV-vis fiber optic probes, 10–12
 United States Pharmacopoeia (USP), 755
 Unstirred water-layer (UWL), 800
- V**
 Variable count time (VCT), 306
 Vibrational density of states (VDOS), 174, 185
 Vibrational spectroscopic imaging
 bivariate analysis, 542
 comparison of, 537
 definition, 524–525
 drug delivery
 MIR imaging, 572–575
 Raman imaging, 575–579
 selected studies, 573
 drug release and dissolution
 MIR imaging, 565–566
 Raman microscopy, 566–571
 selected studies, 567
 drugs and dosage forms
 MIR imaging, 544–554
 near-infrared imaging, 560–562
 Raman imaging, 554–560
 selected studies, 545
 terahertz imaging, 562–564
 MIR, 525–529
 multivariate analysis
 BTEM, 544
 CLS, 543
 MCR, 544
 PCA, 543
 PLS, 543
 Raman (*see* Raman spectroscopy)
 spectral preprocessing
 baseline correction, 539–540
 noise correction, 536–539
 scaling and scatter correction, 540–541
 spectral artefacts, 536
 terahertz, 534–536
 univariate analysis
 bandwidth, 542
 peak integral, 542
 peak intensity, 541
 Vibrational spectroscopy, 77
 Virus-like particles (VLPs), 478
 Viscometer/rheometer-on-a-Chip
 (VROC™), 735
 Volume Bragg grating (VBG), 162
- W**
 White Light Aerosol Spectrometer
 (WELAS), 706
 Wollaston probe, 369
 Wood's anomaly, 50
 Wyatt Technology, 471
- X**
 XCELL program, 301
 Xenon arc lamps, 49
 X-ray femtosecond lasers, 344
 X-ray microtomography, 193, 196
 X-ray photon flux, 312
 X-ray scattering, 340
 diffraction, 340–341
 SAXS (*see* Small angle X-ray scattering
 (SAXS))
 USAXS, 342
- Y**
 Young's modulus, 653, 660, 664